NCT01653574View on ClinicalTrials.gov

A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Breast Neoplasms
Interventions
DRUG

Famitinib Malate

The starting dose of Famitinib Malate will be 25 mg/d. Two dose reductions will be allowed to 20 and then 15 mg/d.

Trial Locations (1)

200032

Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Fudan University

OTHER

NCT01653574 - A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter